Megabac

Colistimethate Sodium ·Incepta Pharmaceuticals Ltd.·IM/IV Injection

0 views 0 reviews

Packages & prices

Pack	Price	Details
2 MIU vial	৳	2 MIU vial: BDT 700.00

Administration

Maintenance dose: 9 MIU/day in 2-3 divided doses. In patients who are critically ill, a loading dose of 9 MIU should be administered.

Renal impairment patients: Dose adjustments in renal impairment patients are necessary. Dose reductions are recommended for patients with creatinine clearance < 50 ml/min. Twice daily dosing is recommended.

Creatinine clearance <50-30 ml/min: daily dose 5.5-7.5 MIU
Creatinine clearance <30-10 ml/min: daily dose 4.5-5.5 MIU
Creatinine clearance <10 ml/min: daily dose 3.5 MIU

Haemodialysis (HD) patients:

No-HD days: 2.25 MIU/day (2.2-2.3 MIU/day).
HD days: 3 MIU/day (Should be given after the HD session) Twice daily dosing is recommended.

Pediatric population: The dose should be based on lean body weight.

Children ≤40 kg: 75,000-150,000 IU/kg/day divided into 3 doses.
Children >40 kg: >150,000 IU/kg/day has been reported in children with cystic fibrosis.

Hepatic impairment patients: There are no data in patients with hepatic impairment. Caution is advised when administering colistimethate sodium in these patients.

Effects

The following adverse reactions have been reported: gastrointestinal upset, tingling of extremities and tongue, slurred speech, dizziness, vertigo and paresthesia, generalized itching, urticaria and rash, fever, increased blood urea nitrogen (BUN), elevated creatinine and decreased creatinine clearance, respiratory distress and apnea, nephrotoxicity and decreased urine output.

Overdosage with colistimethate sodium can cause neuromuscular blockade characterized by paresthesia, lethargy, confusion, dizziness, ataxia, nystagmus, disorders of speech and apnea. Respiratory muscle paralysis may lead to apnea, respiratory arrest and death. Overdosage with the drug can also cause acute renal failure, manifested as decreased urine output and increases in serum concentrations of B.U.N and creatinine. As in any case of overdose, Colistimethate Sodium therapy should be discontinued and general supportive measures should be utilized.

Indications

Colistimethate is indicated for the treatment of acute or chronic infections caused by sensitive strains of certain gram-negative bacilli. It is particularly indicated in the infection caused by sensitive strains of Pseudomonas aeruginosa. Colistimethate is not indicated for infections due to Proteus or Neisseria. Colistimethate is very effective in the treatment of infections due to the following gram-negative organisms: Enterobacter aerogenes, Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa.

Pharmacology

Colistimethate is a surface active agent which penetrates into and disrupts the bacterial cell membrane. Colistimethate is polycationic and has both hydrophobic and lipophilic moieties. It interacts with the bacterial cytoplasmic membrane, changing its permeability. This effect is bactericidal. There is also evidence that polymyxins enter the cell and precipitate cytoplasmic components, primarily ribosomes.

Precautions

Colistimethate should be used with caution in patient with impaired renal function. When actual renal impairment is present, Colistimethate may be used, but the greatest caution should be exercised and the dosage should be reduced in proportion to the extent of the impairment. Colistimethate should be used with caution in neonates, infants and children.

Therapeutic

Other antibacterial preparation

Other brands with the same generic

Packages & prices

Administration

Effects

Indications

Pharmacology

Precautions

Therapeutic

Other brands with the same generic

Aenixit

Aerodyl

Aerodyl

Aerodyl

Aerofen

Aerofen

Aeron

Aeron

Aeron FT

More from Incepta Pharmaceuticals Ltd.

Aenixit

Aerodyl

Aerodyl

Aerodyl

Aerofen

Aerofen

Aeron

Aeron

Leave a review (no account needed)